Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.68 |
| ▸ | PKM | P14618 | 1/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.68 |
| ▸ | XIAP | P98170 | 1/20 | 0.68 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.68 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.64 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.49 |
| ▸ | ANPEP | P15144 | 1/20 | 0.48 |
| ▸ | LAP3 | P28838 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28110902 | 1.00 | ALPI (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Trifluoroacetic Acid SCHEMBL4849158 | 0.91 | SLC15A1 (0.58) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12907015 | 0.87 | SLC15A1 (0.62) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL12323250 | 0.84 | SLC7A5 (0.68) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL23762564 | 0.82 | SLC15A1 (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| D-Phenylalanine SCHEMBL1537448 | 0.82 | SLC7A5 (0.85) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL997986 | 0.82 | SLC15A1 (0.66) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dl-Phenylalanine SCHEMBL21816915 | 0.82 | SLC7A5 (0.85) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Dl-Phenylalanine SCHEMBL1637917 | 0.82 | SLC7A5 (0.85) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL10582687 | 0.82 | SLC15A1 (0.71) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2460814-A1 | PEPTIDIC COMPOUND AND USE OF SAME | Keio University (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120122797-A1 | PEPTIDIC COMPOUND AND USE OF SAME | KEIO UNIVERSITY (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20080019913-A1 | ENKEPAHLIN ANALOGS WITH IMPROVED BIOAVAILABILITY | UNIVERSITY OF ARIZONA OFFICE OF TECHNOLOGY TRANSFER (US) | 2008-01-24 | — | — | US | disclosed |
| EP-1223945-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001026661-A1 | COMPOSITIONS COMPRISING OXOPHOSPHONATE-BASED METALLOPROTEINASE INHIBITORS | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080019913-A1 | ENKEPAHLIN ANALOGS WITH IMPROVED BIOAVAILABILITY | VIP, MME, ELAVL1 | ALPI 2288/4885PKM 2496/4885PTGS1 1845/4885 |
| US-20120122797-A1 | PEPTIDIC COMPOUND AND USE OF SAME | ASNS, ANPEP, NGLY1 | ALPI 4578/4885PKM 2264/4885PTGS1 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.